- End of stabilization operations with partial exercise of the
over-allotment option
- Total amount of the offering increased to EUR 70.4
million
- Implementation of a liquidity contract with NATIXIS ODDO
BHF
Regulatory News:
This document may not be distributed, directly
or indirectly, in the United States, Canada, Australia or
Japan.
AFYREN, a greentech company that offers manufacturers
natural and low-carbon products produced using a technology based
on natural micro-organisms (Paris:ALAFY) (ISIN code: FR- 0014005AC9
mnemonic: ALAFY), has received notification that Joh. Berenberg,
Gossler & Co. KG (Kommanditgesellschaft) (limited
partnership)(“Berenberg”), registered with the Commercial Register
(Handelsregister) of the Local Court (Amtsgericht) of Hamburg under
HRA 42659, acting as Stabilisation Manager in the context of the
first admission to trading of ordinary shares of AFYREN on Euronext
Growth Paris, has undertaken stabilization activities in relation
to the first admission to trading on Euronext Growth Paris of the
following securities:
Issuer:
AFYREN
Securities:
Ordinary shares with a par value of EUR
0.02.
(ISIN: FR0014005AC9)
Offering Size:
8,286,359 ordinary shares (excluding the
overallotment option)
Offer Price:
EUR 8.02 per ordinary share
Market:
Euronext Growth (Paris)
Stabilisation Manager:
Joh. Berenberg, Gossler & Co. KG
(“Berenberg”)
Notification of details of stabilisation transactions in
accordance with Article 6 (2) DelReg (EU) 2016/1052
Pursuant to Article 6, paragraph 2, of Commission Delegated
Regulation (EU) 2016/1052, AFYREN, on the basis of the information
disclosed by Berenberg, hereby communicates that Berenberg has
carried out, during the time period from 1 October 2021 until and
including 29 October 2021, stabilisation measures as further
specified below:
Execution Date
Intermediary
Stabilisation Trading Venue
Buy / Sell
Lowest price (in EUR)
Highest price (in EUR)
Weighted average price (in EUR)
Aggregate amount (in EUR)
Daily total of shares
01.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.3500
8.0200
7.7421
596,854.40
77,092
04.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.1400
7.8800
7.4878
112,256.79
14,992
05.10.2021
Berenberg
Euronext Growth (Paris)
Buy
6.9900
7.6300
7.2297
55,964.79
7,741
06.10.2021
Berenberg
Euronext Growth (Paris)
Buy
6.8200
7.5500
7.3845
205,325.36
27,805
07.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.1300
7.6000
7.5585
164,102.89
21,711
08.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.3600
7.6100
7.5788
113,500.81
14,976
11.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.5500
7.8000
7.7744
103,788.34
13,350
12.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.5000
7.9000
7.8725
118,575.12
15,062
13.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.7500
7.9400
7.9309
109,667.98
13,828
14.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.6800
7.9500
7.8775
113,341.62
14,388
15.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.7100
7.9800
7.9671
131,703.78
16,531
18.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.8300
7.9800
7.9720
110,555.90
13,868
19.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.8200
7.9800
7.9427
107,798.43
13,572
20.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.8200
8.0200
7.9958
115,859.40
14,490
21.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.9500
8.0200
8.0106
49,177.22
6,139
22.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.8500
8.0200
7.9828
16,723.99
2,095
25.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.9200
8.0200
7.9790
9,606.69
1,204
26.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.9400
8.0200
8.0103
29,758.09
3,715
27.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.9400
8.0200
8.0100
35,724.71
4,460
28.10.2021
Berenberg
Euronext Growth (Paris)
Buy
7.9900
8.0200
8.0164
9,395.27
1,172
29.10.2021
Berenberg
Euronext Growth (Paris)
Buy
8.0200
8.0200
8.0200
4,114.26
513
Notification of the end of stabilization measures in
accordance with Article 6 (3) DelReg (EU) 2016/1052
The stabilisation period, which began on 1 October 2021, ended
on 30 October 2021. During this stabilisation period, stabilisation
was carried out in respect of a total number of 298,704 shares in a
price range between EUR 6.8200 (lowest price) and EUR 8.0200
(highest price) solely on Euronext Growth (Paris).
Further details regarding all stabilisation transactions carried
out during the stabilisation period can be found on AFYREN’s
website dedicated to the IPO (https://www.afyren-finance.com/).
Notification of the exercise of the partial exercise of the
Greenshoe-Option in accordance with Article 8 lit. f) DelReg (EU)
2016/1052
In addition, on 30 October 2021, Berenberg acting as stabilizing
agent, acting on its own and on behalf of the Joint Global
Coordinators, exercised in part the over-allotment option to
purchase 490,473 existing shares from the Selling Shareholders at
the initial public offering price of €8.02 per share corresponding
to a total amount of approximately €3.9 million.
As a result, the total number of AFYREN shares sold in its
initial public offering amounts to 8,776,832 shares, including
8,286,359 new ordinary shares and 490,473 existing shares, bringing
the total offering size to €70.4 million
After the exercise of the over-allotment option, AFYREN’s public
float amounts to 16.36% of its total share capital.
Following the offering and the exercise of the over-allotment
option, AFYREN’s share capital will be held as follows:
Shareholders1
After the Exercise of the
Over-Allotment Option
Number of shares
% of share capital and voting
rights
AFY Partners
4 412 425
17.13%
Nicolas Sordet
375 294
1.46%
Jérémy Pessiot
702 794
2.73%
Régis Nouaille
1 558 250
6.05%
Sofinnova Industrial Biotech I
3 313 273
12.86%
Hedgescope Ltd
2 879 950
11.18%
Sofimac Partners
1 219 415
4.73%
Other
3 263 544
12.67%
Mirova
2 164 802
8.40%
BPI
1 657 271
6.43%
Public
4 215 006
16.36%
TOTAL
25 762 024
100.00%
1 On a non-diluted basis
This press release is issued also on behalf of Berenberg
pursuant to Article 6, paragraph 2, of Commission Delegated
Regulation (EU) 2016/1052.
Implementation of a Liquidity Contract with NATIXIS ODDO
BHF
AFYREN announces having appointed NATIXIS and ODDO BHF SCA to
implement a liquidity contract, starting on 1st November 2021, for
a period of one year tacitly renewable.
This contract complies with the decision of the Autorité des
marchés financiers (AMF) n°2021-01 of June, 22 2021 related to the
establishing of liquidity contracts on shares as accepted market
practice and the standard contract of the Association française des
marchés financiers (AMAFI).
This contract with NATIXIS ODDO BHF aims at improving Company’s
shares trading on the regulated market of Euronext Paris.
The following resources have been allocated to the liquidity
account:
The execution of the liquidity contract may be suspended upon
occurrence of the following events or conditions:
- when all conditions provided in Article 5 of the AMF Decision
n°2021-01 June 22, 2021 are met;
- if the share is listed outside the thresholds authorized by the
Company’s Shareholders’ Meeting;
- upon the Company request.
The liquidity contract may be terminated at any time and without
prior notice by AFYREN, at any time by NATIXIS and/or ODDO BHF SCA
subject to fifteen (15) calendar days' notice.
About AFYREN
To meet the growing need for manufacturers to address global
warming and reduce the use of petroleum derivatives in their
production chains, AFYREN produces biomolecules derived from the
recycling of non-food biomass, widely used in the human and animal
nutrition, flavours and fragrances, life sciences, material
sciences and lubricant sectors. This renewable carbon production is
part of a sound circular economy process achieved through the use
of globally patented fermentation technologies developed on the
basis of ten years of research. Founded in 2012 and managed by
Nicolas Sordet and Jérémy Pessiot, AFYREN had 33 employees at its
sites in Lyon, Clermont-Ferrand and Carling Saint-Avold at the end
of December 2020. AFYREN is the winner of the 2030 Global
Innovation Competition in the "Plant proteins and plant chemistry"
category and was selected in the French Tech120 in January 2020 and
2021. In 2018, AFYREN embarked on the construction of its
industrial-scale plant AFYREN NEOXY, which takes the form of a
joint venture with the SPI fund for industrial projects companies
managed by Bpifrance. AFYREN NEOXY will oversee the first
industrial-scale production of AFYREN natural organic acids in the
Grand Est region.
For more information: afyren.com
Warning
This announcement does not, and shall not, in any circumstances
constitute a public offering or an invitation to the public in
connection with any offer in France, United Kingdom, United States,
Canada, Australia, Japan or any other country.
No communication and no information in respect of this
transaction or of AFYREN may be distributed to the public in any
jurisdiction where a registration or approval is required.
This announcement is not a prospectus within the meaning of
Regulation (EU) 2017/1129 of the European Parliament and the
Council of 14 June 2017 (the “Prospectus Regulation”). The
prospectus approved by the AMF is available on the AMF website
(www.amf-france.org/) and the company’s website dedicated to the
IPO (https://www.afyren-finance.com/).
The distribution of this announcement is not made, and has not
been approved, by an authorized person (“authorized person”) within
the meaning of Article 21(1) of the Financial Services and Markets
Act 2000. As a consequence, this announcement is directed only at
persons who (i) are located outside the United Kingdom, (ii) have
professional experience in matters relating to investments and fall
within Article 19(5) (“investment professionals”) of the Financial
Services and Markets Act 2000 (Financial Promotions) Order 2005 (as
amended) and (iii) are persons falling within Article 49(2)(a) to
(d) (high net worth companies, unincorporated associations, etc.)
of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (all such persons together being referred to
as “Relevant Persons”). This announcement is not a prospectus which
has been approved by the Financial Conduct Authority or any other
United Kingdom regulatory authority for the purposes of Section 85
of the Financial Services and Markets Act 2000.
Securities may not be offered or sold in the United States
unless they have been registered under the U.S. Securities Act of
1933, as amended (the “U.S. Securities Act”), or are exempt from
registration. AFYREN does not intend to make a public offer of its
shares in the United States.
The distribution of this document in certain countries may
constitute a breach of applicable law. The information contained in
this document does not constitute an offer of securities for sale
in Canada, Australia or Japan. This announcement may not be
published, forwarded or distributed, directly or indirectly, in the
United States, Canada, Australia or Japan.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211101005386/en/
AFYREN Finance Department Maxime Cordonnier
investisseurs@afyren.com
Investor Relations NewCap Theo Martin Tel: +331 44
71 94 94 afyren@newcap.eu
Media Relations NewCap Nicolas Merigeau Tel: +331
44 71 94 98 afyren@newcap.eu
Alter’Com Conseil Estelle Monraisse Tel: +331 60 41 81 52
estelle@altercom-conseil.fr
Afyren (EU:ALAFY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Afyren (EU:ALAFY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024